[Skip to Content]
[Skip to Content Landing]
May 16, 2001

Updated Guidelines for Cholesterol Management

Author Affiliations

Author Affiliations: Dr Lauer is Contributing Editor and Dr Fontanarosa is Executive Deputy Editor, JAMA.

JAMA. 2001;285(19):2508-2509. doi:10.1001/jama.285.19.2508

During the past decade, there has been tremendous progress in identifying novel risk factors and precisely delineating the role of traditional risk factors associated with coronary heart disease (CHD), with substantial research advances related to the role of lipoproteins and lipid metabolism. Observational studies have established the relationship of serum cholesterol and other lipoproteins with CHD in specific subgroups.1-3 Clinical trials have demonstrated convincing benefits of cholesterol lowering for reducing death and myocardial infarction among patients with CHD4,5 as well as beneficial effects of cholesterol lowering for decreasing the incidence of cardiac events in patients without established coronary disease.6,7 Accurately synthesizing and appropriately applying this rapidly accumulating evidence into clinical practice is essential for reducing the morbidity and mortality associated with coronary disease.